Hofseth BioCare ASA (HBC.OL)
NOK 2.1
(0.95%)
NOK 2.1
(0.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 348.97 Million NOK | 32.69% |
| 2022 | 263 Million NOK | -4.57% |
| 2021 | 275.59 Million NOK | 41.06% |
| 2020 | 195.37 Million NOK | 11.47% |
| 2019 | 175.26 Million NOK | 71.99% |
| 2018 | 101.9 Million NOK | -30.75% |
| 2017 | 147.15 Million NOK | 39.1% |
| 2016 | 105.79 Million NOK | -34.21% |
| 2015 | 160.8 Million NOK | 15.75% |
| 2014 | 138.91 Million NOK | -2.89% |
| 2013 | 143.05 Million NOK | 32.55% |
| 2012 | 107.92 Million NOK | 185.2% |
| 2011 | 37.84 Million NOK | 103.55% |
| 2010 | 18.59 Million NOK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 235.04 Million NOK | -32.65% |
| 2024 Q2 | 247.98 Million NOK | 5.5% |
| 2023 Q3 | 307.92 Million NOK | 4.63% |
| 2023 Q4 | 348.97 Million NOK | 13.33% |
| 2023 FY | 348.97 Million NOK | 32.69% |
| 2023 Q1 | 278.61 Million NOK | 5.94% |
| 2023 Q2 | 294.28 Million NOK | 5.62% |
| 2022 Q1 | 289.9 Million NOK | 5.19% |
| 2022 FY | 263 Million NOK | -4.57% |
| 2022 Q4 | 263 Million NOK | 11.73% |
| 2022 Q3 | 235.38 Million NOK | -21.79% |
| 2022 Q2 | 300.97 Million NOK | 3.82% |
| 2021 Q2 | 244.23 Million NOK | 18.78% |
| 2021 FY | 275.59 Million NOK | 41.06% |
| 2021 Q1 | 205.62 Million NOK | 5.25% |
| 2021 Q3 | 267.1 Million NOK | 9.36% |
| 2021 Q4 | 275.59 Million NOK | 3.18% |
| 2020 Q2 | 203.39 Million NOK | 19.03% |
| 2020 Q1 | 170.88 Million NOK | -2.5% |
| 2020 FY | 195.37 Million NOK | 11.47% |
| 2020 Q3 | 217.82 Million NOK | 7.09% |
| 2020 Q4 | 195.37 Million NOK | -10.31% |
| 2019 Q3 | 186.02 Million NOK | 3.14% |
| 2019 FY | 175.26 Million NOK | 71.99% |
| 2019 Q1 | 178.3 Million NOK | 74.98% |
| 2019 Q4 | 175.26 Million NOK | -5.78% |
| 2019 Q2 | 180.35 Million NOK | 1.15% |
| 2018 Q1 | 136.79 Million NOK | -7.04% |
| 2018 FY | 101.9 Million NOK | -30.75% |
| 2018 Q4 | 101.9 Million NOK | 17.95% |
| 2018 Q2 | 155.12 Million NOK | 13.4% |
| 2018 Q3 | 86.39 Million NOK | -44.31% |
| 2017 Q2 | 80.65 Million NOK | -20.72% |
| 2017 FY | 147.15 Million NOK | 39.1% |
| 2017 Q4 | 147.15 Million NOK | 45.97% |
| 2017 Q1 | 101.73 Million NOK | -3.84% |
| 2017 Q3 | 100.81 Million NOK | 24.99% |
| 2016 Q4 | 105.79 Million NOK | -7.14% |
| 2016 FY | 105.79 Million NOK | -34.21% |
| 2016 Q1 | 160.08 Million NOK | -0.44% |
| 2016 Q2 | 181.56 Million NOK | 13.41% |
| 2016 Q3 | 113.92 Million NOK | -37.25% |
| 2015 Q1 | 152.93 Million NOK | 10.09% |
| 2015 FY | 160.8 Million NOK | 15.75% |
| 2015 Q4 | 160.8 Million NOK | 3.99% |
| 2015 Q3 | 154.63 Million NOK | 1.41% |
| 2015 Q2 | 152.48 Million NOK | -0.29% |
| 2014 Q2 | 107.77 Million NOK | -33.76% |
| 2014 FY | 138.91 Million NOK | -2.89% |
| 2014 Q1 | 162.68 Million NOK | 13.73% |
| 2014 Q4 | 138.91 Million NOK | 8.41% |
| 2014 Q3 | 128.14 Million NOK | 18.9% |
| 2013 Q4 | 143.05 Million NOK | 6.58% |
| 2013 Q2 | 127.93 Million NOK | -5.99% |
| 2013 Q1 | 136.07 Million NOK | 26.09% |
| 2013 FY | 143.05 Million NOK | 32.55% |
| 2013 Q3 | 134.22 Million NOK | 4.92% |
| 2012 Q3 | 86.13 Million NOK | 55.34% |
| 2012 Q1 | 40.83 Million NOK | 7.92% |
| 2012 FY | 107.92 Million NOK | 185.2% |
| 2012 Q2 | 55.44 Million NOK | 35.78% |
| 2012 Q4 | 107.92 Million NOK | 25.3% |
| 2011 Q4 | 37.84 Million NOK | 23.05% |
| 2011 Q3 | 30.75 Million NOK | 0.0% |
| 2011 FY | 37.84 Million NOK | 103.55% |
| 2010 FY | 18.59 Million NOK | 0.0% |
| 2010 Q4 | 18.59 Million NOK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Arctic Bioscience AS | 41.69 Million NOK | -736.994% |
| Aqua Bio Technology ASA | 15.72 Million NOK | -2119.533% |
| ArcticZymes Technologies ASA | 30.02 Million NOK | -1062.256% |
| BerGenBio ASA | 46.85 Million NOK | -644.743% |
| PCI Biotech Holding ASA | 5 Million NOK | -6868.431% |
| Thor Medical ASA | 58.91 Million NOK | -492.393% |
| Ultimovacs ASA | 69.64 Million NOK | -401.061% |